IceCure Medical (NASDAQ:ICCM) & Labcorp (NYSE:LH) Head-To-Head Survey

Labcorp (NYSE:LH) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Earnings and Valuation

This table compares Labcorp and IceCure Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95 billion	1.61	$876.50 million	$10.46	26.10
IceCure Medical	$3.38 million	6.52	-$15.06 million	($0.24)	-1.25

Labcorp has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Labcorp and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Labcorp	6.28%	16.16%	7.62%
IceCure Medical	-445.61%	-221.04%	-118.89%

Insider and Institutional Ownership

95.9% of Labcorp shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Labcorp has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Labcorp and IceCure Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0	3	8	0	2.73
IceCure Medical	1	1	1	0	2.00

Labcorp presently has a consensus target price of $307.70, suggesting a potential upside of 12.69%. IceCure Medical has a consensus target price of $2.64, suggesting a potential upside of 775.42%. Given IceCure Medical’s higher possible upside, analysts clearly believe IceCure Medical is more favorable than Labcorp.

Summary

Labcorp beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About Labcorp

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.